Tumor microenvironment has significant influence in therapeutic response and clinical outcome. Combination therapy is more effective in cancer treatment compared with monotherapy. Any chemical or drug that targets tumor microenvironment pathway, will be a boon to combination cancer chemotherapy. Combination therapy through micronutrient may have added advantage in clinical applications. Selenium (Se) is an essential micronutrient; Se in the form of Se nanoparticles (SeNPs) show efficient anticancer properties and may have the potential to target tumor niche such as hypoxic environment. The aim of this study was to find out the anticancer effect of SeNPs on cell line HepG2 under hypoxic condition and also to evaluate their effect on the translocation of hypoxia-inducible factors (HIFs) from cytoplasm to nucleus that help the cells to survive under hypoxic condition. It was found that the SeNPs induce HepG2 cell death in normoxic and hypoxic conditions, however, hypoxic condition showed higher LD50. SeNP concentration is directly proportional to cell death in both the conditions. Furthermore, intracellular accumulation of Se is not affected by hypoxia. SeNP-induced HepG2 cell death is due to increased DNA damage, nuclear condensation, and mitochondrial membrane potential disturbance. Furthermore, SeNPs were also found to decrease the translocation of HIFs from cytosol to the nucleus. After analyzing the results, it is concluded that SeNP treatment disturbs tumor niche through the inhibition of HIFs' translocation from cytosol to nucleus. SeNPs in synergy with primary drug, such as doxorubicin (DOX), may enhance the anticancer efficacy of DOX through regulation of HIFs, warranting further research.
Get full access to this article
View all access options for this article.
References
1.
Abd El-MoneimOM, Abd El-RahimAH, HafizNA. Evaluation of selenium nanoparticles and doxorubicin effect against hepatocellular carcinoma rat model cytogenetic toxicity and DNA damage. Toxicol Rep, 2018; 5:771–776; doi:10.1016/j.toxrep.2018.07.003
2.
AhmadMS, YasserMM, SholkamyEN, et al.Anticancer activity of biostabilized selenium nanorods synthesized by Streptomyces bikiniensis strain Ess-amA-1. Int J Nanomed, 2015; 10:3389–3401; doi: 10.2147/IJN.S82707
3.
AkinyemijuT, AberaS, AhmedM, et al.The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the Global, regional, and National level: Results from the global burden of disease study 2015. JAMA Oncol, 2017; 3(12):1683–1691; doi:10.1001/jamaoncol.2017.3055
4.
AsadpourR, AliyoldashiMH, SaberivandA, et al.Ameliorative effect of selenium nanoparticles on the structure and function of testis and in vitro embryo development in aflatoxin B1-exposed male mice. Andrologia, 2020; 52(11):e13824; doi:10.1111/and.13824
5.
BlasiakJ. DNA-damaging anticancer drugs - A perspective for DNA repair- oriented therapy. Curr Medl Chem, 2017; 24(15):1488–1503; doi.org/10.2174/0929867324666170124145557
6.
BurroughsSK, KaluzS, WangD, et al.Hypoxia inducible factor pathway inhibitors as anticancer therapeutics. Future Med Chem, 2013; 5(5):10.4155/fmc.13.17; doi: 10.4155/fmc.13.17
7.
CaoL, ZhaoS, YangQ, et al.Chidamide combined with doxorubicin induced p53-driven cell cycle arrest and cell apoptosis reverse multidrug resistance of breast cancer. Front Oncol, 2021; 11:614458; doi: 10.3389/fonc.2021.614458
8.
CameronSJ, HosseinianF, WillmoreWG. A current overview of the biological and cellular effects of nanosilver. Int J Mol Sci, 2018; 19(7):2030; doi:10.3390/ijms19072030
9.
ChintalaS, TóthK, CaoS, et al.Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1α. Cancer Chemother Pharmacol, 2010; 66(5):899–911; doi: 10.1007/s00280-009-1238-8
10.
CuiD, MaJ, LiangT, et al.Selenium nanoparticles fabricated in laminarin polysaccharides solutions exert their cytotoxicities in HepG2 cells by inhibiting autophagy and promoting apoptosis. Int J Biol Macromol, 2019; 137:829–835; doi:10.1016/j.ijbiomac.2019.07.031
11.
DeeksED. Belzutifan: First approval. Drugs, 2021; 81(16):1921–1927; doi: 10.1007/s40265-021-01606-x
12.
DesaiA, SandhuS, LaiJP, SandhuDS. Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review. World J Hepatol, 2019; 11(1):1–18; doi:10.4254/wjh.v11.i1.1
13.
EstesC, RazaviH, LoombaR, et al.Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology, 2018; 67(1):123–133; doi: 10.1002/hep.29466
14.
EstevezH, Garcia-LidonJC, Luque-GarciaJL, et al.Effects of chitosan-stabilized selenium nanoparticles on cell proliferation, apoptosis and cell cycle pattern in HepG2 cells: Comparison with other selenospecies. Colloids Surf B Biointerfaces, 2014; 122:184–193; doi: 10.1016/j.colsurfb.2014.06.062
15.
FallahJ, RiniBI. HIF Inhibitors: Status of current clinical development. Curr Oncol Reports, 2019; 21(1):6; doi: 10.1007/s11912-019-0752-z
16.
FuX, YangY, LiX, et al.RGD peptide-conjugated selenium nanoparticles: Antiangiogenesis by suppressing VEGF-VEGFR2-ERK/AKT pathway. Nanomaterials (Basel), 2018; 8(1):2; doi: 10.3390/nano8010002
17.
GarboS, Di GiacomoS, ŁażewskaD, et al.Selenium containing agents acting on cancer-a new hope?. Pharmaceutics, 2022; 15(1):104; doi:10.3390/pharmaceutics15010104
18.
HalimVA, García-SantistebanI, WarmerdamDO, et al.Doxorubicin-induced DNA damage causes extensive ubiquitination of ribosomal proteins associated with a decrease in protein translation. Mol Cell Prot, 2018; 17(12):2297–2308; doi.org/10.1074/mcp.RA118.000652
19.
HeC, SunXP, QiaoH, et al.Downregulating hypoxia-inducible factor-2α improves the efficacy of doxorubicin in the treatment of hepatocellular carcinoma. Cancer Sci, 2012; 103(3):528–534; doi.org/10.1111/j.1349-7006.2011.02177.x
20.
HuP, ZuoZ, WangF, et al.The protective role of selenium in AFB1-induced tissue damage and cell cycle arrest in Chicken's bursa of fabricius. Biol Trace Elem Res, 2018; 185(2):486–496; doi:10.1007/s12011-018-1273-6
21.
HuangY, HeL, LiuW, et al.Selective cellular uptake and induction of apoptosis of cancer-targeted selenium nanoparticles. Biomaterials, 2013; 34(29):7106–7116; doi.org/10.1016/j.biomaterials.2013.04.067
22.
KannanS, MohanrajK, PrabhuK, et al.Synthesis of selenium nanorods with assistance of biomolecule. Bull Mater Sci, 2014; 37:1631–1635; doi.org/10.1007/s12034-014-0712-z
23.
KhalilHMA, AzouzRA, HozyenHF, et al.Selenium nanoparticles impart robust neuroprotection against deltamethrin-induced neurotoxicity in male rats by reversing behavioral alterations, oxidative damage, apoptosis, and neuronal loss. Neurotoxicology, 2022; 91:329–339; doi:10.1016/j.neuro.2022.06.006
24.
KieliszekM. Selenium-fascinating microelement, properties and sources in food. Molecules, 2019; 24(7):1298; doi.org/10.3390/molecules24071298
25.
KorbeckiJ, SimińskaD, Gąssowska-DobrowolskaM, et al.Chronic and cycling hypoxia: Drivers of cancer chronic inflammation through HIF-1 and NF-κB activation: A review of the molecular mechanisms. Int J Mol Sci, 2021; 22(19):10701; doi:10.3390/ijms221910701
26.
LiuT, ZengL, JiangW, et al.Rational design of cancer-targeted selenium nanoparticles to antagonize multidrug resistance in cancer cells. Nanomedicine, 2015; 11(4):947–958; doi.org/10.3390/molecules24071298
27.
LuoH, WangF, BaiY, et al.Selenium nanoparticles inhibit the growth of HeLa and MDA-MB-231 cells through induction of S phase arrest. Colloids Surf B Biointerfaces, 2012; 94:304–308; doi.org/10.1016/j.colsurfb.2012.02.006
28.
MarreroJA, KulikLM, SirlinCB, et al.Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice guidance by the American Association for the Study of Liver Diseases. Hepatology, 2018; 68(2):723–750; doi.org/10.1002/hep.29913
29.
Meyenberg Cunha-dePM, NoletoGR, de Oliveira PetkowiczCL, et al.Hypoxia protects against the cell death triggered by oxovanadium-galactomannan complexes in HepG2 cells. Cell Mol Biol Lett, 2019; 24:18; doi:10.1186/s11658-019-0135-3
30.
MoldoveanuT. Apoptotic mitochondrial portion by a growing list of pore-forming BCL-2 family proteins. Bioessays, 2023; 45(3):e2200221; doi:10.1002/bies.202200221
31.
Morán-SerradillaC, Angulo-ElizariE, Henriquez-FiguereoA, et al.Seleno metabolites and their precursors: A new dawn for several illnesses?. Metabolites, 2022; 12(9):874; doi.org/10.3390/metabo12090874
32.
NasirA, KhanA, LiJ, et al.Nanotechnology, a tool for diagnostics and treatment of cancer. Curr Top Med Chem, 2021; 21(15):1360–1376; doi:10.2174/1568026621666210701144124
33.
Osada-OkaM, KuwamuraH, ImamiyaR, et al.Suppression of the doxorubicin response by hypoxia-inducible factor-1α is strictly dependent on oxygen concentrations under hypoxic conditions. Eur J Pharmacol, 2022; 920:174845; doi.org/10.1016/j.ejphar.2022.174845
34.
RamamurthyCH, SampathKS, ArunkumarP, et al.Green synthesis and characterization of selenium nanoparticles and its augmented cytotoxicity with doxorubicin on cancer cells. Bioprocess Biosyst Eng, 2013; 36(8):1131–1139; doi: 10.1007/s00449-012-0867-1
35.
RustumYM, ChintalaS, DurraniFA, et al.Non-coding micro RNAs and hypoxia-inducible factors are selenium targets for development of a mechanism-based combination strategy in clear-cell renal cell carcinoma-bench-to-bedside therapy. Int J Mol Sci, 2018; 19(11):3378; doi: 10.3390/ijms19113378
36.
SkalickovaS, MilosavljevicV, CihalovaK, et al.Selenium nanoparticles as a nutritional supplement. Nutrition, 2017; 33:83–90; doi.org/10.1016/j.nut.2016.05.001
37.
SonnaLA, CullivanML, SheldonHK, et al.Effect of hypoxia on gene expression by human hepatocytes (HepG2). Physiol Genomics, 2003; 12(3):195–207; doi: 10.1152/physiolgenomics.00104.2002
StickelF. Alcoholic cirrhosis and hepatocellular carcinoma. Adv Exp Med Biol, 2015; 815:113–130; doi.org/10.1007/978-3-319-09614-8_7
40.
SunD, LiuY, YuQ, et al.The effects of luminescent ruthenium (II) polypyridyl functionalized selenium nanoparticles on bFGF-induced angiogenesis and AKT/ERK signaling. Biomaterials, 2013; 34(1):171–180; doi: 10.1016/j.biomaterials.2012.09.031
41.
TanS, BaiJ, XuM, et al.Thioredoxin-1 activation by pterostilbene protects against doxorubicin-induced hepatotoxicity via inhibiting the NLRP3 inflammasome. Front Pharmacol, 2022; 13:841330; doi:10.3389/fphar.2022.841330
42.
ThirunavukkarasuC, SinghPVJ, ThangavelM, et al.Dietary influence of selenium on the incidence of N-nitrosodiethylamine-induced hepatoma with reference to drug and glutathione metabolizing enzymes. Cell Biochem Funct, 2002:20(4);347–356; doi: 10.1002/cbf.979
43.
TolosaL, DonatoMT, Gómez-LechónMJ. General cytotoxicity assessment by means of the MTT assay. Methods Mol Biol, 2015; 1250:333–348; doi: 10.1007/978-1-4939-2074-7_26
44.
VincetiM, FilippiniT, JablonskaE, et al.Safety of selenium exposure and limitations of selenoprotein maximization: Molecular and epidemiologic perspectives. Environ Res, 2022; 211:113092; doi:10.1016/j.envres.2022.113092
45.
WangKS, MaJ, MiC, et al.Kamebakaurin inhibits the expression of hypoxia-inducible factor-1α and its target genes to confer antitumor activity. Oncol Rep, 2016; 35(4):2045–2052; doi.org/10.3892/or.2016.4576
46.
WangY, ChenP, ZhaoG, et al.Inverse relationship between elemental selenium nanoparticle size and inhibition of cancer cell growth in vitro and in vivo. Food Chem Toxicol, 2015; 85:71–77; doi.org/10.1016/j.fct.2015.08.006
47.
WangY, FuL. Forms of selenium affect its transport, uptake and glutathione peroxidase activity in the Caco-2 cell model. Biol Trace Elem Res, 2012; 149:110–116; doi.org/10.1007/s12011-012-9395-8
48.
WangY, YiY, YaoJ, et al.Isoginkgetin synergizes with doxorubicin for robust co-delivery to induce autophagic cell death in hepatocellular carcinoma. Acta Biomater, 2022; 153:518–528; doi:10.1016/j.actbio.2022.09.035
49.
WilliamsKJ, TelferBA, XenakiD, et al.Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. Radiother Oncol, 2005; 75(1):89–98; doi.org/10.1016/j.radonc.2005.01.009
50.
WuQ, YouL, NepovimovaE, et al.Hypoxia-inducible factors: Master regulators of hypoxic tumor immune escape. J Hematol Oncol, 2022; 15(1):77; doi:10.1186/s13045-022-01292-6
51.
XieQ, DengW, YuanX, et al.Selenium-functionalized liposomes for systemic delivery of doxorubicin with enhanced pharmacokinetics and anticancer effect. Eur J Phar Biopharm, 2018; 122:87–95; doi.org/10.1016/j.ejpb.2017.10.010
52.
ZhangW, ZhangB, ChenXP. Adjuvant treatment strategy after curative resection for hepatocellular carcinoma. Front Med, 2021; 15(2):155–169; doi:10.1007/s11684-021-0848-3
53.
ZhengW, YinT, ChenQ, et al.Co-delivery of Se nanoparticles and pooled SiRNAs for overcoming drug resistance mediated by P-glycoprotein and class III β-tubulin in drug-resistant breast cancers. Acta Biomater, 2016; 31:197–210; doi.org/10.1016/j.actbio.2015.11.041
54.
ZhouN, XiaoH, LiTK, et al.DNA damage-mediated apoptosis induced by selenium compounds. J Biol Chem, 2003; 278(32):29532–29537; doi: 10.1074/jbc.M301877200
55.
ZhuH, ChenXP, LuoSF, et al.Involvement of hypoxia-inducible factor 1α in multidrug resistance induced by hypoxia in HepG2 cells. J Exp Clin Cancer Res, 2005; 24:565–574.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
